1461097220-1388f627-4947-4425-980e-8e1502ba9009

1. The method of increasing moisture retention in potting soil comprising the steps of:
providing a plurality of separate pieces of biodegradable, moisture absorbent, environmentally friendly soil additives, said additives comprising pieces of cotton material approximately one-half inch square;
providing a given volume of potting soil;
combining the soil additives and potting soil by adding the soil additives to the potting soil;
mixing the soil additives substantially evenly throughout the volume of potting soil;
planting one or more growing plants within the potting soil;
adding water to the potting soil;
absorbing moisture from the water into the soil additives;
expanding the size of the soil additives due to the absorption of the water;
retaining the moisture within the soil additives, thus creating a soil additive mixture containing at least five to ten times more water than is contained in potting soil with no additives;
disbursing moisture from the soil additives to the potting soil and to the plants over a prolonged period of time; and
maintaining moisture in the potting soil for said prolonged period of time and for a period of time at least five to ten times longer than potting soil containing no additives.
2. The method of claim 1 wherein the potting soil to soil additive ratio is 15 to 1.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An immune response altering agent comprising:
(a) a first domain comprising one or more components selected from the group consisting of T cell epitopes, B cell epitopes, and TLR-binding proteins or TLR-binding domains thereof; and; and
(b) a second domain comprising a heterologous target molecule against which an immune response is desired;
wherein the first domain alters an immune response in a subject against the heterologous target.
2. The immune response altering agent of claim 1 wherein the T cell epitopes are derived from more than one source.
3. The immune response altering agent of claim 1 wherein the T cell epitopes are derived from one or more sources selected from the group consisting of an infectious agent, a virus, a bacterium, a tumor, an autoantigen, a fungus, a yeast, mycoplasma, a self antigen, and a non-self antigen.
4-13. (canceled)
14. The immune response altering agent of claim 1 wherein the first domain is covalently attached to the second domain via a peptide bond.
15. The immune response altering agent of claim 1 wherein the first domain is chemically coupled to the second domain.
16. The immune response altering agent of claim 1 wherein the first domain is noncovalently attached to the second domain.
17-20. (canceled)
21. The immune response altering agent of claim 1 wherein the first domain is attached to the second domain via biotin.
22. The immune response altering agent of claim 1 wherein the first domain is attached to the second domain via an antibody.
23. The immune response altering agent of claim 1 wherein the heterologous target comprises a protein.
24-27. (canceled)
28. The immune response altering agent of claim 1 wherein the heterologous target comprises a tumor antigen.
29. The immune response altering agent of claim 1 wherein the heterologous target comprises an autoantigen.
30-31. (canceled)
32. The immune response altering agent of claim 1 wherein the heterologous target comprises a S. pneumoniae protein.
33-37. (canceled)
38. The immune response altering agent of claim 1 wherein the T cell epitopes are generated synthetically.
39. The immune response altering agent of claim 1 wherein the T cell epitopes are generated recombinantly.
40. The immune response altering agent of claim 1 wherein the T cell epitopes comprise CD4+ T helper cell epitopes.
41. The immune response altering agent of claim 1 wherein the T cell epitopes comprise CD8+ cytotoxic T cell epitopes.
42. The immune response altering agent of claim 1 wherein the T cell epitopes comprise CD4+ T helper cell epitopes and CD8+ cytotoxic T cell epitopes.
43. The immune response altering agent of claim 1 wherein the agent is a polynucleotide encoding a fusion protein.
44. The immune response altering agent of claim 1 wherein the agent is a fusion protein.
45. A composition comprising an immune response altering agent of claim 1.
46. A composition comprising an immune response altering agent of claim 1 in combination with a physiologically acceptable excipient.
47. A composition comprising an immune response altering agent of claim 1 in combination with an adjuvant.
48-52. (canceled)
53. A method for inducing an immune response to a target comprising administering to a subject an immune response altering agent of claim 1.
54. The method of claim 53 wherein the immune response comprises a CD8 cytotoxic T cell mediated response.
55. The method of claim 53 wherein the immune response comprises a CD4 T helper cell mediated response.
56. The method of claim 53 wherein the immune response comprises predominantly a Th1 type response.
57. The method of claim 53 wherein the immune response comprises predominantly a Th2 type response.
58. A T cell epitope cassette comprising multiple T cell epitopes, wherein said cassette alters an immune response to a heterologous target when administered as a fusion with, or attached to the heterologous target.
59. A composition comprising:
(a) a heterologous target molecule; and
(b) one or more first domains, said one or more first domains comprising a polypeptide sequence selected from the group consisting of:
(i) either one of the full length polypeptide sequences set forth in SEQ ID NOs:214-215 (ESAT 6 and CFP10); and
(ii) a fragment of either one of the full length polypeptide sequences set forth in SEQ ID NO:214-215, wherein the fragment induces an immune response that is not substantially reduced as compared to an immune response induced by the full length polypeptide.
60-61. (canceled)
62. The composition of claim 59 wherein the polypeptide comprises the sequence set forth in SEQ ID NO:214 and the sequence set forth in SEQ ID NO:215.
63-64. (canceled)
65. The composition of claim 59 wherein the first domain comprises at least one polypeptide comprising any one or more of the sequences set forth in SEQ ID NOs:216-293.
66. A method for inducing or enhancing an immune response to a heterologous target molecule in an individual comprising administering to the individual a composition comprising:
(a) the heterologous target molecule; and
(b) one or more first domains, said one or more first domains comprising a polypeptide sequence selected from the group consisting of:
(i) either one of the full length polypeptide sequences set forth in SEQ ID NOs:214-215; and
(ii) a fragment of either one of the full length polypeptide sequences set forth in SEQ ID NO:214-215, wherein the fragment induces an immune response that is not substantially reduced as compared to an immune response induced by the full length polypeptide.
67. The method of claim 66 wherein the polypeptide comprises the sequence set forth in SEQ ID NO:215.
68. The method of claim 66 wherein the polypeptide comprises the sequence set forth in SEQ ID NO:216.
69. The method of claim 66 wherein the polypeptide comprises the sequence set forth in SEQ ID NO:215 and the sequence set forth in SEQ ID NO:216.
70-71. (canceled)
72. The method of claim 66 wherein the first domain comprises at least one polypeptide comprising any one or more of the sequences set forth in SEQ ID NOs:216-293.
73. The method of claim 66 wherein the immune response is a predominantly Th1-type response.
74. The method of claim 66 wherein the immune response is a predominantly Th2-type response.
75. The method of claim 66 wherein the immune response is a Th0-type response.
76. The method of claim 66 wherein the immune response is a CD4+ T cell response.
77. The method of claim 66 wherein the immune response is a CD8+ T cell response.
78. The method of claim 66 wherein the target molecule comprises an antigen selected from the group consisting of a viral coat protein, influenza neuraminidase, influenza hemmaglutinin, HIV gp160 or derivatives thereof, SARS coat protein, Herpes virion proteins, WNV capsid proteins, pneumococcal PsaA, PspA, LytA, Nisseria gonnorhea OMP or Nisseria gonnorhea surface proteases.
79. A method for inducing or enhancing an immune response to a target molecule in an individual comprising administering to the individual a composition comprising:
(a) the target molecule; and
(b) one or more polypeptides or fragments thereof, wherein said one or more polypeptides or fragments thereof comprise at least one T cell epitope.
80-81. (canceled)
82. The immune response altering agent of claim 1 wherein said agent is attached to a targeting molecule.
83. The immune response altering agent of claim 82 wherein said targeting molecule is an antibody or antigen-binding fragment thereof.